Marksans Pharma Announcements
USFDA approval for Benzonatate Capsules USP, 100 mg & 200 mg (Rx)
01 Apr, 2026 | 12:11pm • Source: BSE
Intimation of Closure of Trading Window for Quarter and Year ending March 31, 2026
26 Mar, 2026 | 02:45pm • Source: BSE
Newspaper publication regarding opening of special window for re-lodgement of the transfer request for physical shares
12 Mar, 2026 | 02:22pm • Source: BSE
Marksans Pharma Limited has informed the Exchange about opening of Special Window for Re-lodgment of Transfer Requests of Physical Shares
11 Mar, 2026 | 05:00pm • Source: NSE
Public notice regarding opening of Special Window for Re-lodgement of Transfer Requests of Physical Shares for information of Shareholders of the Company
11 Mar, 2026 | 04:31pm • Source: BSE
Marksans Pharma Limited submits transcript of Investors/Analyst meet on Q3 9M FY 26 Unaudited Financial Results held on February 06, 2026
12 Feb, 2026 | 04:03pm • Source: BSE
Audio Recording of investor(s) / analyst(s) meet Conference Call on Q3 & 9M FY26 Financial Results
06 Feb, 2026 | 06:25pm • Source: BSE
Newspaper Publication of Un-Audited Financial Results for the Quarter and Nine months ended 31 December, 2025
06 Feb, 2026 | 04:58pm • Source: BSE
Press Release regarding unaudited financial results for Q3 FY 26
05 Feb, 2026 | 02:02pm • Source: BSE
Marksans Investors Presentation Q3 and 9M FY 26
05 Feb, 2026 | 01:57pm • Source: BSE
Unaudited financial results for the quarter and nine months ended 31 December, 2025
05 Feb, 2026 | 01:44pm • Source: BSE
Outcome of Board Meeting - Unaudited Financial Results for the quarter and nine months ended 31 December, 2025
05 Feb, 2026 | 01:34pm • Source: BSE
Incorporation of two new wholly owned subsidiary Companies
27 Jan, 2026 | 02:16pm • Source: BSE
The Company has scheduled a conference call for analysts and investors on Friday, February 06, 2026 at 04:00 PM (IST) to discuss the Unaudited Financial...
22 Jan, 2026 | 04:35pm • Source: BSE
Certificate received from RTA under regulation 74(5) of SEBI (DP) regulations 2018, for the quarter ended December 31, 2025
13 Jan, 2026 | 03:31pm • Source: BSE
Marksans Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 05/02/2026 ,inter alia, to consider and...
09 Jan, 2026 | 03:32pm • Source: BSE
Intimation for closure of trading window for the quarter ended December, 2025
26 Dec, 2025 | 11:49am • Source: BSE
Marksans Pharma Limited submits Transcript of Investors/analysts meet on Q2 FY26 Unaudited Financial Results held on November 14, 2025 at 05:00 pm.
21 Nov, 2025 | 12:13pm • Source: BSE
Marksans Pharma Limited''s wholly owned subsidiary Marksans Pharma Inc receives US FDA approval of its ANDA for Loperamide Hydrochloride 2mg tablets.
19 Nov, 2025 | 11:15am • Source: BSE
Marksans Pharma Limited''s wholly owned subsidiary Relonchem Limited receives Marketing Authorisation for its products from UK MHRA.
17 Nov, 2025 | 11:18am • Source: BSE